A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure (AUGMENT-HFII)
Sponsor: LoneStar Heart, Inc.
Listed as NCT03082508, this NA trial focuses on Dilated Cardiomyopathy and Heart Failure and remains ongoing. Sponsored by LoneStar Heart, Inc., it has been updated 6 times since 2017, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status NA
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Feb 2024 [monthly]
Not Yet Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
▶ Show 1 earlier version
-
Apr 2017 — Feb 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- LoneStar Heart, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.